Clinical Trials Browser

Phase 3 × HER2-positive Breast Cancer × pyrotinib × Clear all

NCT03588091 2025-08-22

Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer

Phase 3 Completed

HER2-positive Breast Cancer